BioNTech Keeps Its Buy Ratings as Price Targets Slide and a Lung-Safety Signal Clouds a Phase-3 Win

BioNTech closed Friday up 2.3%, a modest move that masks a more interesting week for the German biotech. Analysts spent Wednesday trimming their price targets while leaving their buy calls untouched, and the company's cancer program delivered both a statistical win and a safety caveat worth weighing carefully.

Confidence, repriced

Morgan Stanley cut its target to $106 from $114 on Wednesday, according to media reports, while keeping its "Overweight" rating. UBS lowered its own target to $125 from $135 and likewise held its buy recommendation. Other houses trimmed their marks too, all while staying constructive on the stock.

That pattern — a positive rating paired with a lower number — is the week's real signal. It is optimism expressed under tighter valuation discipline rather than a change of heart. For investors, the takeaway is that the buy case now rests on whether operational and clinical progress can actually fill the gap between current prices and those reduced targets.

A profit line to anchor the story

The financial backdrop arrived Tuesday, when BioNTech reported a third-quarter 2026 net profit of EUR 184.5 million — a sharp reversal from the EUR 28.7 million loss booked in the same period a year earlier. Revenue, however, fell to EUR 1,289.2 million, which the company attributed to weaker demand for COVID-19 vaccines. Management also raised the lower bound of its full-year revenue guidance and now expects between EUR 1.7 billion and EUR 1.9 billion.

Should investors sell immediately? Or is it worth buying BioNTech?

So the picture is two-sided: a stronger bottom line sitting next to a shrinking vaccine business. The profit gives the valuation a concrete reference point; the pipeline is supposed to supply the future. A credible read on BioNTech needs both halves in view.

The trial that cuts both ways

The DYNASTY-Breast02 Phase 3 study of trastuzumab pamirtecan met its primary endpoint, with a statistically significant improvement in progression-free survival. BioNTech itself described the gain as moderate. At the same time, the company reported a higher frequency of interstitial lung disease than in earlier studies, including a small share of severe and fatal events.

That combination is the crux of the investment case. Statistical significance is a genuine plus, but a moderate benefit paired with serious side effects demands sober weighting — the two facts belong in the same assessment, not separate ones. A more favorable view of the cancer program would require the efficacy to clearly justify the tolerability burden, and the company's own disclosure of elevated lung-disease rates makes that bar a high one.

BioNTech at a turning point? This analysis reveals what investors need to know now.

A collaboration with a condition attached

Separately, BioNTech's pumitamig is slated for testing in combination with Gilead's sacituzumab govitecan as a first-line treatment for locally advanced or metastatic triple-negative breast cancer with low or absent PD-L1 expression. The planned global Phase 3 ROSETTA Breast-01 trial remains contingent on regulatory approval — a concrete clinical framework with a clear precondition for proceeding.

That contingency is a fitting emblem of the whole story: reported profits on one side, research plans whose next steps hinge on approvals and trial readouts on the other. The analysts' buy ratings reflect faith in that outlook; their lower targets set a more cautious frame around it. Whether the confidence holds depends on BioNTech converting its financial base into clinical momentum — and on whether the benefit of its cancer drugs, severe side effects included, ultimately carries the weight.

Ad

BioNTech Stock: New Analysis - 9 November

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...